TuisORX • STO
add
Orexo AB
Vorige sluiting
kr 23,35
Dagwisseling
kr 23,25 - kr 24,50
Jaarwisseling
kr 12,50 - kr 43,40
Markkapitalisasie
824,38 m SEK
Gemiddelde volume
36,63 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
STO
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (SEK) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 3,30 m | -97,94% |
Bedryfskoste | 80,70 m | -66,63% |
Netto inkomste | 724,80 m | 723,22% |
Netto winsgrens | 21,96 k | 30 373,80% |
Wins per aandeel | — | — |
EBITDA | -46,80 m | -550,00% |
Effektiewe belastingkoers | -0,09% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (SEK) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 912,40 m | 639,98% |
Totale bates | 1,30 mjd | 119,03% |
Totale aanspreeklikheid | 812,20 m | 12,63% |
Totale ekwiteit | 490,60 m | — |
Uitstaande aandele | 34,71 m | — |
Prys om te bespreek | 1,65 | — |
Opbrengs op bates | -21,96% | — |
Opbrengs op kapitaal | -32,02% | — |
Kontantvloei
Netto kontantverandering
| (SEK) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 724,80 m | 723,22% |
Kontant van bedrywe | 806,20 m | 12 903,23% |
Kontant van beleggings | — | — |
Kontant van finansiering | 4,80 m | 197,96% |
Netto kontantverandering | 806,70 m | 9 503,57% |
Beskikbare kontantvloei | 40,78 m | 427,83% |
Meer oor
Orexo is a Swedish pharmaceutical company that develops improved pharmaceuticals based on innovative formulation technologies that meet large medical needs. Through presence its in the US market, drugs and digital therapies are commercialized to treat opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with partners. Wikipedia
Gestig
1995
Webwerf
Werknemers
72
